BioCentury
ARTICLE | Company News

Regeneron, Sanofi antibody discovery deal ending

August 4, 2017 1:08 AM UTC

In its 2Q17 earnings announcement, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said its 2007 antibody discovery agreement with Sanofi (Euronext:SAN; NYSE:SNY) will not be extended beyond its Dec. 31, 2017 expiration. The end of the deal -- under which Praluent alirocumab, Dupixent dupilumab, Kevzara sarilumab, REGN2810 (SAR439684), REGN3500 (SAR440340) and REGN3767 were generated -- will not affect the companies’ co-development and co-commercialization agreements covering those products.

With the deal's expiration, Regeneron will no longer receive annual funding from Sanofi, which comprised $100 million per year from 2007 through 2010, $160 million from 2010 through 2012, $145 million in 2015, and $130 million in 2016 and 2017. ...